drugset / Trial / NCT03950700

Bupivacaine in the Treatment of Postoperative Pain of Impacted Third Molar Extraction

NCT03950700 ↗

Phase 4 Completed 40 enrolled CES University
RandomizedParallel-groupSingle-blindSupportive care

Summary

The third molars are the teeth that are most frequently included and impacted, extraction is one of the most performed treatments by maxillofacial surgeons in their clinical practice. Its surgical extraction is accompanied by an inflammatory process, which generates pain, edema and trismus. The use of alternatives that offer prolonged analgesia, like the use of bupivacaine, reduce the pain of the patient after an extraction of third molars, allows the reduction of morbidity and the rapid return to daily activities. In addition, it allows a better experience in the dental consultation. Investigators hypothesis is: Irrigation of the alveolus with 4 ml of 0.5% bupivacaine is effective for the reduction of post-operative pain in extraction of impacted lower third molars

Timeline

Start
2019-06-01
Primary completion
2019-12-31
Completion
2020-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine-epinephrine Unknown 0.5 % Other
Subject Bupivacaine-epinephrine Unknown 4 ml Other